Internet Archive Scholar

Live virus neutralization testing in convalescent and vaccinated subjects against 19A, 20B, 20I/501Y.V1 and 20H/501.V2 isolates of SARS-CoV-2 [article]

Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, Kahina Saker, Bruno Lina, Laurence Josset, Mary-Anne Trabaud, Guillaume Thiery, Elisabeth Botelho-Nevers, Stéphane Paul, Paul Verhoeven (+5 others)
2021 medRxiv   pre-print

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (434.8 kB)
https://web.archive.org/web/20210715054914/https://www.medrxiv.org/content/medrxiv/early/2021/05/11/2021.05.11.21256578.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

SARS-CoV-2 mutations appeared recently and can lead to conformational changes in the spike protein and probably induce modifications in antigenicity. In this study, we wanted to assess the neutralizing capacity of antibodies to prevent cell infection, using a live virus neutralisation test. Methods: Sera samples were collected from different populations: two-dose vaccinated COVID-19-naïve healthcare workers (HCWs; Pfizer-BioNTech BNT161b2), 6-months post mild COVID-19 HCWs, and critical
more » ... patients. We tested various clades such as 19A (initial one), 20B (B.1.1.241 lineage), 20I/501Y.V1 (B.1.1.7 lineage), and 20H/501Y.V2 (B.1.351 lineage). Results: No significant difference was observed between the 20B and 19A isolates for HCWs with mild COVID-19 and critical patients. However, a significant decrease in neutralisation ability was found for 20I/501Y.V1 in comparison with 19A isolate for critical patients and HCWs 6-months post infection. Concerning 20H/501Y.V2, all populations had a significant reduction in neutralising antibody titres in comparison with the 19A isolate. Interestingly, a significant difference in neutralisation capacity was observed for vaccinated HCWs between the two variants whereas it was not significant for the convalescent groups. Conclusion: Neutralisation capacity was slightly reduced for critical patients and HCWs 6-months post infection. No neutralisation escape could be feared concerning the two variants of concern in both populations. The reduced neutralising response observed towards the 20H/501Y.V2 in comparison with the 19A and 20I/501Y.V1 isolates in fully immunized subjects with the BNT162b2 vaccine is a striking finding of the study.
doi:10.1101/2021.05.11.21256578 fatcat:yns4aaenzvfbpakz3upaem3gru
Citation

Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, Kahina Saker, Bruno Lina, Laurence Josset, Mary-Anne Trabaud, Guillaume Thiery, Elisabeth Botelho-Nevers, Stéphane Paul, Paul Verhoeven, Thomas Bourlet, Sylvie Pillet, Florence Morfin, Sophie Trouillet-Assant, Bruno Pozzetto. "Live virus neutralization testing in convalescent and vaccinated subjects against 19A, 20B, 20I/501Y.V1 and 20H/501.V2 isolates of SARS-CoV-2." medRxiv (2021)